These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1161 related articles for article (PubMed ID: 27658867)
1. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey. Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G; Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867 [TBL] [Abstract][Full Text] [Related]
2. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R; Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603 [TBL] [Abstract][Full Text] [Related]
3. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016. Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167 [TBL] [Abstract][Full Text] [Related]
4. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463 [TBL] [Abstract][Full Text] [Related]
5. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148 [TBL] [Abstract][Full Text] [Related]
6. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA; Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460 [TBL] [Abstract][Full Text] [Related]
7. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. TenoRes Study Group Lancet Infect Dis; 2016 May; 16(5):565-575. PubMed ID: 26831472 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina. Bissio E; Barbás MG; Kademián S; Bouzas MB; Salomón H; Cudolá A; Giuliano SF; Falistocco C Antivir Ther; 2017; 22(7):625-629. PubMed ID: 28234630 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial. Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716 [TBL] [Abstract][Full Text] [Related]
10. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey. Ávila-Ríos S; García-Morales C; Valenzuela-Lara M; Chaillon A; Tapia-Trejo D; Pérez-García M; López-Sánchez DM; Maza-Sánchez L; Del Arenal-Sánchez SJ; Paz-Juárez HE; Quiroz-Morales VS; Mehta SR; Smith DM; León-Juárez EA; Magis-Rodríguez C; Reyes-Terán G; J Antimicrob Chemother; 2019 Apr; 74(4):1044-1055. PubMed ID: 30597094 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique. Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381 [TBL] [Abstract][Full Text] [Related]
13. Protease and gag diversity and drug resistance mutations among treatment-naive Mexican people living with HIV. Climaco-Arvizu S; Flores-López V; González-Torres C; Gaytán-Cervantes FJ; Hernández-García MC; Zárate-Segura PB; Chávez-Torres M; Tesoro-Cruz E; Pinto-Cardoso SM; Bekker-Méndez VC BMC Infect Dis; 2022 May; 22(1):447. PubMed ID: 35538426 [TBL] [Abstract][Full Text] [Related]
14. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793 [TBL] [Abstract][Full Text] [Related]
15. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey. Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031 [TBL] [Abstract][Full Text] [Related]
16. Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15. Bissio E; Barbás MG; Bouzas MB; Cudolá A; Salomón H; Espínola L; Fernández Giuliano S; Kademián S; Mammana L; Ornani ML; Ravasi G; Vila M; Zapiola I; Falistocco C J Antimicrob Chemother; 2017 Feb; 72(2):504-510. PubMed ID: 27789684 [TBL] [Abstract][Full Text] [Related]
18. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings. Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262 [TBL] [Abstract][Full Text] [Related]
19. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali. Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120 [TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]